Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Rating) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 853,900 shares, a growth of 16.2% from the February 13th total of 735,100 shares. Approximately 2.9% of the shares of the company are sold short. Based on an average trading volume of 402,600 shares, the short-interest ratio is currently 2.1 days.
Aligos Therapeutics Stock Down 2.9 %
Shares of NASDAQ ALGS opened at $1.32 on Monday. The stock has a market capitalization of $56.52 million, a price-to-earnings ratio of -0.58 and a beta of 2.50. The stock’s fifty day simple moving average is $1.62 and its 200 day simple moving average is $1.26. Aligos Therapeutics has a 52-week low of $0.84 and a 52-week high of $2.99.
Wall Street Analyst Weigh In
ALGS has been the topic of a number of research reports. Piper Sandler boosted their price objective on Aligos Therapeutics from $3.00 to $7.00 in a research note on Monday, January 16th. Jefferies Financial Group raised Aligos Therapeutics from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $2.50 to $3.00 in a research note on Friday, January 6th.
Institutional Inflows and Outflows
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.
- Get a free copy of the StockNews.com research report on Aligos Therapeutics (ALGS)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.